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Abstract This study aimed to compare the efficacy and
safety aspects of three anthracycline-based regimens as
neoadjuvant chemotherapy in primary breast cancer. Five-
hundred and one patients with clinical stage I–III invasive
breast cancer were randomly assigned to receive four
cycles of neoadjuvant chemotherapy with either CEFci arm
(5-Fu 200 mg/m2 daily by 24-h continuous infusion and
epirubicin 100 mg/m2 and cyclophosphamide 600 mg/m2
intravenous bolus on day 1), CEF arm (cyclophosphamide
600 mg/m2, epirubicin 100 mg/m2, and 5-Fu 600 mg/m2
i.v. on day 1), or EC arm (epirubicin 100 mg/m2 and
cyclophosphamide 600 mg/m2 i.v. on day 1). The patho-
logic responses to chemotherapy were assessed according
to the Miller and Payne grading system (MP). A total of
485 patients were included in the intent-to-treat population.
Breast pathologic complete response (pCR) rate was
18.9 % (31/164) in CEFci arm, 15.0 % (24/160) in CEF
arm, and 12.4 % (20/161) in EC arm (P = 0.266). MP
grading system 4/5 response rate was significantly higher in
CEFci arm than that in CEF arm and EC arm (44.5, 31.3
and 27.3 %, respectively, P = 0.003). There was no sig-
nificant difference on grade III/IV neutropenia among three
arms (P = 0.538), but thrombocytopenia, decreased
hemoglobin, and elevated aminotransferase appeared to be
observed more in CEFci arm (P = 0.040, 0.059, and 0.073,
respectively). CEFci did not reach a higher pCR rate
compared with CEF or EC in patients with primary breast
cancer. The potential advantage of CEFci in improving
pathologic response still requires further research. The
accompanied hematologic and biochemical toxicities, and
the catheter-related complications should also be noted.
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Introduction
Neoadjuvant chemotherapy is the standard treatment for
locally advanced and inflammatory breast cancer and is
applied to downstage tumors initially not suitable for
resection or breast-conserving surgery [1, 2]. Moreover, the
application of neoadjuvant chemotherapy in operable
breast cancer is gradually increasing because of the
advantages of using the tumor as an early in vivo measure
of response to treatment [3]. Previous studies showed that
tumor response to neoadjuvant chemotherapy was associ-
ated with prognosis of breast cancer patients, and those
who achieved the pathologic complete response (pCR)
potentially obtain better survival [4, 5]. Currently, anthra-
cycline-based polychemotherapy regimens are frequently
used in the adjuvant treatment in breast cancer, and 5-flu-
orouracil (5-Fu) is also commonly included [6–8]. In
contrast with intravenous bolus 5-Fu, continuous infusion
of 5-Fu showed a more significant efficacy and less adverse
reactions with a relatively short half-life (\30 min) [9, 10].
In order to search for a more effective regimen of 5-Fu
combined with epirubicin and cyclophosphamide, we
designed a single-center, randomized, parallel controlled
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study to compare the efficacy and safety aspects of three
different regimens: cyclophosphamide/epirubicin/intra-
venous bolus 5-Fu (CEF), cyclophosphamide/epirubicin/
continuous infusional 5-Fu (CEFci), and cyclophosphami
de/epirubicin (EC) with absence of 5-Fu.
Methods
Patients
We included in the study female clinical stage I–III
(cT1–3N0–2M0) breast cancer patients aged B65 years old
with histologically confirmed invasive breast cancer by
core needle biopsy in our breast center from March 2011 to
July 2014. All subtypes defined by immunohistochemistry
hormone receptor (HR) and human epidermal growth fac-
tor receptor 2 (HER2) status were enrolled in the study,
including HR-positive and HER2-negative subtype
(HR?HER2-), triple-negative subtype (HR-HER2-),
and HER2-positive subtype (HER2?). Further relevant
eligibility criteria included no history of other malignan-
cies; adequate hematologic function (absolute neutrophils
count C1.5 9 109/L, platelets C100 9 109/L, and hemo-
globin C100 g/L); adequate hepatic and renal functions
[alanine aminotransferase (ALT)/aspartate aminotrans-
ferase (AST) B2.5 times the institutional upper normal
limit (UNL), serum bilirubin B1.5 9 UNL, and serum
creatinine B1.7 mg/dl]; and normal cardiac function.
Patients with pregnancy or in lactation; with known or
suspected distant metastases diagnosed by chest X-ray,
abdominal and pelvic ultrasound, or bone scans; or with
currently uncontrolled diseases (e.g., cardiac dysrhythmias,
unstable diabetes) or active infection were excluded.
Patients with the Miller and Payne (MP) grading results
were included in the intention-to-treat analyses (ITT), and
those without neoadjuvant chemotherapy or without sur-
gery were excluded. All the enrolled patients were pro-
vided with written informed consent.
Study design
This is a single-center, randomized, and parallel controlled
study designed to compare the efficacy and safety aspects
among three anthracycline-based regimens for neoadjuvant
chemotherapy in patients with primary breast cancer, reg-
istered with ClinicalTrials.gov, number NCT01199432.
Patients were centrally randomly assigned (1:1:1) to
receive one of the three neoadjuvant chemotherapy: Arm
A: cyclophosphamide, epirubicin, and continuous infu-
sional 5-fluorouracil (CEFci); Arm B: cyclophosphamide,
epirubicin, and intravenous bolus 5-fluorouracil (CEF); or
Arm C: cyclophosphamide and epirubicin (EC). After
completion of four cycles of neoadjuvant chemotherapy,
patients underwent surgery and possible following adjuvant
treatment (chemotherapy, trastuzumab, radiotherapy, or
endocrinotherapy) according to the guidelines of NCCN
and St. Gallen [11].
Treatment
All eligible patients received cyclophosphamide
(C, 600 mg/m2) plus epirubicin (E, 100 mg/m2) adminis-
tered as intravenous boluses on day 1 of every 3 weeks. In
arm A (CEFci regimen), 5-fluorouracil (5-Fu, 200 mg/m2)
was administered as a 24-h continuous infusion using an
ambulatory pump via Hickman line through a central
venous catheter for 12 weeks; in arm B (CEF regimen),
5-Fu (600 mg/m2) was administered as intravenous bolus
on day 1 every 3 weeks; however, in arm C (EC regimen),
5-Fu was not included.
Toxicity and chemotherapy delay
Toxicity was assessed according to common toxicity cri-
teria grade by laboratory examination, including routine
blood tests on day 7, 10, 14, 21 and biochemistry test on
day 21 before every next cycle of chemotherapy. Recom-
binant human granulocyte colony-stimulating factor was
applied at 5 lg/kg/d subcutaneously for three days if
leukocyte count\2.0 9 109/L and/or absolute neutrophils
count \1.0 9 109/L, and antibiotics were prescribed
simultaneously for any episode of febrile neutropenia.
Recombinant human interleukin-11 support was given at
24 million IU/d subcutaneously for seven days if platelets
count \50 9 109/L, and liver-protection therapy was
conducted if ALT/AST level was found higher than 2.5
times the institutional UNL.
Treatment was delayed for one or two weeks when
absolute neutrophils count\1.5 9 109/L, platelets count
\100 9 109/L, hemoglobin count \80 g/L, ALT/AST -
C 2.5 9 UNL, and/or when blood urea nitrogen/creatinine
was found abnormal during hematologic and biochemical
tests on day 21 before every next cycle of chemotherapy.
We terminated neoadjuvant chemotherapy if treatment was
delayed for more than two weeks, if there was incidence of
disease progression or severer adverse events, or according
to the patient’s wills.
Response assessment
Tumor clinical response to chemotherapy was both asses-
sed by ultrasonography after completion of the second and
the fourth cycles of treatment before surgery using the
World Health Organization criteria. Complete response
(CR) was defined as complete resolution of all masses and
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abnormalities. Partial response (PR) was defined as a
C50 % reduction in the product of the bidimensional tumor
measurements without progression of any lesion or
appearance of any new disease. For stable disease (SD),
there was a\50 % reduction or\25 % increase, whereas
for progressive disease (PD), there was a C25 % increase
or appearance of new disease [12].
Tissue slices from core needle biopsy both before
neoadjuvant chemotherapy and surgery were collected
from the Department of Pathology, and the histologic
response to chemotherapy in breast was assessed by two
senior pathologists using the Miller and Payne grading
system: Grade 1 (G1): no change or some alteration to
individual malignant cells but no reduction in overall
cellularity; Grade 2 (G2): a minor loss of tumor cells but
overall cellularity still high—up to 30 % loss; Grade 3
(G3): between an estimated 30 and 90 % reductions in
tumor cells; Grade 4 (G4): a marked disappearance of
tumor cells such that only small clusters or widely dis-
persed individual cells remain—more than 90 % loss of
tumor cells; and Grade 5 (G5): no malignant cells iden-
tifiable in sections from the site of the tumor—only vas-
cular fibroelastotic stroma remains often containing
macrophages. However, ductal carcinoma in situ may be
present [13]. Each pathologist scored the tumor tissues
independently, and agreement by consensus was achieved
if necessary. In this study, we defined grade 5 (G5) as
pCR [14].
In this study, the primary end point was pathologic
complete response, and the secondary endpoints were MP
response, clinical response, and adverse effect.
Sample size calculation and statistics
Based on an expected rate of pathologic complete response
with 10 % in arm C (EC regimen), 25 % in arm B (CEF
regimen), and 40 % in arm A (CEFci regimen), 456
patients were calculated as a minimum sample size to
provide 80 % power, with a = 0.05 (two-sided) level of
significance to detect an absolute difference in pCR rate in
excess of 15 % among arms. With possible follow-up loss
of less than 10 % of patients, the total sample size was
determined as 501.
Number or percentage was used to describe categorical
variables. The comparison of pCR rate or clinicopathologic
characteristics among the arms was performed with Chi
square test or Fisher’s exact test. Logistic regression model
was carried out to compare the odds ratios (ORs) for
pathologic response among the arms in multivariate anal-
yses. All statistical tests were two-sided, and bonferroni
correction was used for multiple comparisons. P val-
ues\ 0.05 were considered statistically significant.
Sample size calculation and statistical analyses were




Between March 11, 2011 and July 17, 2014, a total of 501
patients (167 assigned to each arm) were enrolled from the
Breast Center, Peking University Cancer Hospital. As
Table 1 shows, characteristics (including age, menstrual
status, tumor size, lymph node status, pathological type,
histologic grade, IHC-defined subtype, ki-67 index, and
surgery type) were balanced across the three treatment
arms. Four (two in arm B and two in arm C) patients were
found to be ineligible after randomization, leaving 497
patients in total receiving neoadjuvant chemotherapy. Of
the four ineligible patients, three underwent surgery
immediately due to uncontrolled hypertension, severe
anemia, and thrombocytopenia, respectively, and the
remaining one refused any treatment. Twelve (3 in arm A,
5 in arm B, and 4 in arm C) of 497 patients did not undergo
surgery due to their being lost to follow-up, leaving 485
with available pathologic response to chemotherapy in
breast for the ITT analyses. Of these 485 patients, the
following patients were omitted: 10 (9 in arm A and 1 in
arm C) who were against protocols and selected regimens
independently after randomization; and 10 (all in arm A)
who had terminated continuous infusional 5-fluorouracil
through central venous catheters after completion of one
cycle of neoadjuvant chemotherapy (six with catheter
thrombus, one with catheter infection, and three since they
refused). Neoadjuvant chemotherapy was discontinued on
14 patients (7 in arm A, 4 in arm B, and 3 in arm C) due to
severe adverse events, including febrile neutropenia, hep-
atic injury, nausea and vomiting, oral ulcer, epilepsy, atrial
fibrillation, and palpitation. According to tumor response
and/or patient’s wills, neoadjuvant treatment was adjusted
for surgery, endocrinotherapy, or followed by four cycles
of paclitaxel regimen on 28 patients (3 in arm A, 12 in arm
B, and 13 in arm C) (Fig. 1).
Efficacy
The primary analyses of tumor response to neoadjuvant
chemotherapy were carried out in the intention-to-treat
population of 485 patients: 164 (33.8 %) in arm A, 160
(32.9 %) in arm B, and 161 (33.2 %) in arm C (Table 2).
Of these 485 patients, a total of 75 (15.5 %) achieved the
pCR in breast, and there were no statistically significant
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differences in pCR rates among the three arms (18.9 vs.
15.0, and 12.4 %, P = 0.266) (Table 2). The percentages
of patients with clinical CR or PR was 63.4 % (104/164) in
arm A, 53.8 % (86/160) in arm B, and 52.8 % (85/161) in
arm C, with no statistically significant differences
(P = 0.101) (Table 2). As Table 3 shows, the percentage
of patients with MP 4/5 response in breast was higher in
arm A than that in arm B (44.5 vs. 31.3 %) with
statistically significant difference (P = 0.004), and an OR
of 2.081 (95 % CI 1.264–3.427), but the percentage in arm
B was similar to that in arm C (31.3 vs. 27.3 %), with no
statistically significant difference (OR 0.821, 95 % CI
0.489–1.378, P = 0.455). Besides treatment regimens,
pathologic response to neoadjuvant chemotherapy in breast
was also associated with tumor size, ki-67 index, and IHC-
defined subtype.
Table 1 Characteristics of 501
patients enrolled










[35 152 (91.0) 150 (89.8) 156 (93.4)
B35 15 (9.0) 17 (10.2) 11 (6.6)
Menstrual status
Postmenopause 48 (28.7) 52 (31.1) 67 (40.1)
Premenopause 119 (71.3) 115 (68.9) 100 (59.9)
Tumor sizea
T B 2 cm 30 (18.0) 29 (17.4) 28 (16.8)
2 cm\T B 5 cm 120 (71.9) 130 (77.8) 130 (77.8)
T[ 5 cm 17 (10.1) 8 (4.8) 9 (5.4)
Lymph node status
Negative 56 (33.5) 46 (27.5) 39 (23.4)
Positive 109 (65.3) 116 (69.5) 121 (72.5)
Unknown 2 (1.2) 5 (3.0) 7 (4.2)
Pathological type
Invasive ductal carcinoma 157 (94.0) 154 (92.2) 154 (92.2)
Othersb 10 (6.0) 13 (7.8) 13 (7.8)
Histologic grade
I 7 (4.2) 10 (6.0) 10 (6.0)
II 110 (65.9) 104 (62.3) 112 (67.0)
III 39 (23.3) 38 (22.7) 30 (18.0)
Unknown 11 (6.6) 15 (9.0) 15 (9.0)
IHC-defined subtype
HR?HER2- 84 (50.2) 88 (52.7) 83 (49.7)
HR-HER2- 40 (24.0) 42 (25.1) 42 (25.1)
HER2? 33 (19.8) 26 (15.6) 30 (18.0)
Unknownc 10 (6.0) 11 (6.6) 12 (7.2)
Ki-67 index
C25 % 100 (59.9) 99 (59.3) 98 (58.7)
\25 % 67 (40.1) 68 (40.7) 69 (41.3)
Surgery type
Breast-conserving surgery 47 (28.1) 43 (25.7) 41 (24.6)
Mastectomy 117 (70.1) 119 (71.3) 121 (72.4)
Unknown 3 (1.8) 5 (3.0) 5 (3.0)
a Measured by ultrasonography
b Include infiltrating lobular carcinoma, medullary carcinoma, colloid carcinoma, metaplastic carcinoma,
neuroendocrine carcinoma, cribriform carcinoma, and micropapillary carcinoma
c IHC immunohistochemistry HR hormone receptorHER2 human epidermal growth factor receptor 2
d No further assessment of HER2 by fluorescence in situ hybridization (FISH) in 32 HER2 (2?) patients
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Hematologic and biochemical toxicity
The percentages of patients with grade III/IV neutropenia
were 80.5 % (132/164) in arm A, 74.4 % (119/160) in arm
B, and 72.0 % (116/161) in arm C, respectively, and there
was no statistically significant difference among the three
groups (P = 0.538) (Table 4). Hemoglobin count B
109 g/L (grade I–IV) was observed in 56 (34.1 %) of 164
patients in arm A, 48 (30.0 %) of 160 patients in arm B,
and 36 (22.4 %) of 161 patients in arm C, and the
Randomization
(1:1:1)










(included in ITT analyses) 
9 protocol violations
14 adverse events 
3 refused ci 5-Fu
3 treatment change 
 1 underwent surgery 
after cycle 3 
 2 followed by T 4 
501 patients enrolled
167 assigned to CEF
(Arm B)
167 assigned to EC
(Arm C)
165 began chemotherapy 165 began chemotherapy
135 completed CEFci 4 
before surgery 
5 had no surgery due to 
lost to follow-up  
160 underwent surgery
(included in ITT analyses) 




12 treatment change 
 1 underwent surgery 
after cycle 3 
 11 followed by T 4 
4 had no surgery due to
lost to follow-up  
161 underwent surgery
(included in ITT analyses) 




13 treatment change 
 3 underwent surgery 
after cycle 2 
 9 followed by T 4 
1 received arimidex
1 EPI replaced by THP
3 had no surgery due to 
lost to follow-up  
Fig. 1 CONSORT flow diagram. C cyclophosphamide, E epirubicin, F 5-fluorouracil, ci continuous infusion, ITT intention-to-treat, T paclitaxel,
EPI epirubicin, THP pirarubicin
Table 2 Pathologic and
clinical responses in breast to
neoadjuvant chemotherapy







EC (N = 161)
N (%)
Pathologic complete response (G5) 31 (18.9) 24 (15.0) 20 (12.4) 0.266
MP4/5 response (G4/5)a 73 (44.5) 50 (31.3) 44 (27.3) 0.003
CR ? PR 104 (63.4) 86 (53.8) 85 (52.8) 0.101
CR complete responsePR partial response
a Miller and Payne grading system
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difference was close to statistical significance (P = 0.059).
The percentages of patients with thrombocytopenia were
9.1 % (15/164) in arm A, including 1.2 % with grade III/
IV; 2.5 % (4/160) in arm B; and 7.5 % (12/161) in arm C,
and the difference was statistically significant (P = 0.040).
The percentages of patients with ALT/AST[ 2.5 times the
institutional UNL were 9.1 % (15/164) in arm A, 4.4 % (7/
160) in arm B, and 3.7 % (6/161) in arm C, respectively,
and the difference was close to statistical significance
(P = 0.073).
Discussion
Clinically, 5-fluorouracil (5-Fu) has been commonly used
as a single agent or in combination with other
chemotherapies in breast cancer treatment for decades
[15–17]. Continuous infusional 5-Fu combined with
epirubicin and cisplatin (ECciF) regimen appears to be
more active than conventional regimens for both advanced
breast cancer and large operable breast cancer, but the
contribution of 5-Fu to the anthracycline–cycloph
Table 3 Associations of chemotherapy regimens and tumor characteristics with pathologic response
Characteristics Pathologic response Multivariate analysis
G4/G5 (N = 167)
N (%)
G1/G2/G3 (N = 318)
N (%)
OR 95 % CI P value
Age (years) 0.239
[35 156 (35.2) 287 (64.8) 1.331 0.600–2.950 0.482
B35 11 (26.2) 31 (73.8) 1
Menstrual status 0.044
Postmenopause 65 (40.6) 95 (59.4) 1.359 0.862–2.142 0.186
Premenopause 102 (31.4) 223 (68.6) 1
Tumor sizea \0.001 \0.001
T B 2 cm 44 (52.4) 40 (47.6) 10.415 3.244–33.438 \0.001
2 cm\T B 5 cm 118 (32.0) 251 (68.0) 3.897 1.322–11.485 0.014
T[ 5 cm 5 (15.6) 27 (84.4) 1
Lymph node status 0.059 0.261
Unknown 1 (8.3) 11 (91.7) 0.196 0.023–1.676 0.137
Positive 111 (33.1) 224 (66.9) 1.126 0.695–1.825 0.630
Negative 55 (39.9) 83 (60.1) 1
Pathological type 0.342
Invasive ductal arcinoma 152 (33.9) 297 (66.1) 0.563 0.261–1.213 0.142
Othersb 15 (41.7) 21 (58.3) 1
IHC-defined subtypec \0.001 0.007
Unknownd 10 (31.3) 22 (68.8) 1.358 0.584–3.158 0.478
HR-/HER2- 56 (46.3) 65 (53.7) 1.922 1.105–3.343 0.021
HER2? 39 (45.9) 46 (54.1) 2.615 1.467–4.661 0.001
HR?/HER2- 62 (25.1) 185 (74.9) 1
Ki-67 index \0.001
C25 % 123 (42.6) 166 (57.4) 2.716 1.699–4.340 \0.001
\25 % 44 (22.4) 152 (77.6) 1
Treatment regimen 0.003 0.001
CEFci 73 (44.5) 91 (55.5) 2.081 1.264–3.427 0.004
EC 44 (27.3) 117 (72.7) 0.821 0.489–1.378 0.455
CEF 50 (31.3) 110 (68.8) 1
a Measured by ultrasonography
b Include infiltrating lobular carcinoma, medullary carcinoma, colloid carcinoma, metaplastic carcinoma, neuroendocrine carcinoma, cribriform
carcinoma, and micropapillary carcinoma
c IHC immunohistochemistry, HR hormone receptor, HER2 human epidermal growth factor receptor 2
d No further assessment of HER2 by fluorescence in situ hybridization (FISH) in 32 HER2 (2?) patients
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osphamide regimens (AC or EC) has not been well defined
[18, 19].
Our study showed that the outcome of administration of
low-dose continuous infusional 5-Fu (200 mg/m2) 24 h
daily for 21 days was not superior to that of high-dose
intravenous bolus (600 mg/m2) on day 1, with no statisti-
cally significant difference in pathologic complete
responses in breast between CEFci arm and CEF arm,
although the percentage of patients achieving MP 4/5
response in breast in CEFci arm was almost as twice as that
in CEF arm. Compared to the treatment without 5-Fu in the
regimen, 5-Fu administrated as intravenous bolus 600 mg/
m2 on day 1 did not show any significant advantage of
efficacy improvement, with MP 4/5 response rate of
31.3 % in CEF arm versus 27.3 % in EC arm. In the
TOPIC trial which randomly designed 426 patients with
operable breast cancer tumor C3 cm to receive six cycles
of either epirubicin–cisplatin and continuous infusional
5-Fu (infusional ECisF) or doxorubicin–cyclophosphamide
(AC) before surgery to compare the response rates between
the two arms [20], no statistically significant differences
were observed both in overall response rates (77 vs. 75 %,
P = 0.6) and in the pCR rates (both 16 %, P = 1.0). The
discrepant results between our study and those of the
TOPIC trial possibly arise from the different chemothera-
peutic agent doses and regimens employed.
In the aspect of hematologic toxicity, no statistically
significant differences were observed in the incidences of
grade III/IV neutropenia among the three arms in our study
(80.5, 74.4, and 72.0 %, respectively, P = 0.538), but
thrombocytopenia and decreased hemoglobin appeared to
be observed more in CEFci arm compared with the other
two arms, with differences being statistically significant or
close to statistical significance (P = 0.040,and 0.059,
respectively). In terms of biochemical toxicity, however,
elevated aminotransferase occurred in 9.1 % of patients
receiving CEFci regimen, which is higher than 4.4 % with
CEF regimen and 3.7 % with EC regimen, and the differ-
ence was close to statistical significance (P = 0.073).
It is noteworthy that nine patients in CEFci arm rejected
the protocols after randomization and before the beginning
of the first cycle of chemotherapy, since they were worried
that their daily life would be influenced by probable
inconvenience of continuous infusional 5-Fu and periodic
maintenance of central venous catheters. Similarly, three
patients refused continuous infusional 5-Fu during the
process of treatment, and ci 5-Fu was ceased in another
seven patients after the removal of catheters due to
catheter-related events, such as thrombus and infection.
However, treatment plans were changed apparently more
frequently in patients receiving EC or CEF regimen
according to tumor response assessed by ultrasonography
after completion of two or four cycles of neoadjuvant
chemotherapy, and 25 patients with SD or PD received
either four cycles of paclitaxel chemotherapy or
endocrinotherapy, or underwent surgery immediately
according to physician’s decisions and/or patient’s wills.
To our knowledge, this is the only randomized con-
trolled clinical study comparing the efficacy and safety
aspects of different anthracycline-based regimens in pri-
mary breast cancer neoadjuvant chemotherapy between
standard epirubicin-cyclophosphamide (EC) regimen and
EC combined with 5-Fu, as well as between continuous
infusion and intravenous bolus as two different adminis-
tration approaches of 5-Fu.
In conclusion, although this study shows that there are
no statistically significant differences in pCR rates among
the three arms, the potential advantage of the
Table 4 Hematologic and
biochemical toxicity







EC (N = 161)
N (%)
Toxicity (grades I–IV)
Neutrophil count 153 (93.3) 148 (92.5) 145 (90.1) 0.538
Hemoglobin count 56 (34.1) 48 (30.0) 36 (22.4) 0.059
Platelet count 15 (9.1) 4 (2.5) 12 (7.5) 0.040
ALT/AST 49 (29.9) 34 (21.3) 35 (21.7) 0.125
Toxicity (grades III/IV)
Neutrophilcount 132 (80.5) 119 (74.4) 116 (72.0) 0.186
Hemoglobin count 5 (3.0) 1 (0.6) 1 (0.6) 0.106
Platelet count 2 (1.2) 0 (0.0) 0 (0.0) 0.140
ALT/AST 15 (9.1) 7 (4.4) 6 (3.7) 0.073
The toxicity is scored according to the CTC common toxicity criteria ALT alanine aminotransferase AST
aspartate aminotransferase
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administration of low-dose continuous infusional 5-Fu in
improving the efficacy of anthracycline-based chemother-
apy still requires further research. However, the accom-
panied hematologic and biochemical toxicities, catheter-
related complications, and poor compliance with inconve-
nient daily life should also be noted in patients receiving
the CEFci regimen.
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